A Strategic Approach to Mitigating Risks While Advancing Clinical Trial Methods
Optimizing Hybrid Study Design
Enhancing Patient Safety
Improving Participant Engagement and Retention
Accelerating Study Milestones
Conclusion: Bringing It All Together
ObvioHealth successfully conducted a clinical trial for RedHill Biopharma to test the safety and efficacy of an oral medication for the treatment of COVID-19 symptoms. We designed this decentralized study to be conducted where the majority of patients recover from illness—in their homes. When the trial was launched in 2021, its unique combination of home health visits, electronic patient-reported outcomes (ePRO), and remote monitoring devices was pioneering—COVID-19 studies were typically conducted inside hospitals.Download PDF Version
ObvioHealth designed a remote study using a combination of home health visits, digital monitoring devices, and ePRO.
RedHill Biopharma followed patients daily for two months, collecting vital signs that were imperative to the study’s endpoints. Data collection of this magnitude would not have been possible within the strictures of a traditional, in-person trial.
The successful study endpoints achieved in early 2022 empowered RedHill Biopharma with the data needed to initiate discussions with regulators.
reduction in hospitalizations due to COVID-19
reduction in reported new severe COVID-19 symptoms
“When glitches arose, as would be expected in a novel situation such as this, the ObvioHealth team was available to work through the problems and correct them for subsequent patient entry. I’d feel very comfortable recommending ObvioHealth.”
Dr. Terry Plasse
Medical Director at RedHill Biopharma